Meta analysis of comparative study on ziprasidone in the treatment of schizophrenia
LI Jiang-yon
Abstract
LI Jiang-yon
Abstract
Objective To study the efficacy and side effects of ziprasidone in treatment of patients with schizophrenia.Methods A total of 14 comparative studies of ziprasidone and the other antipsychotics in the treatment of patients with schizophrenia were analyzed by meta-analysis in therapeutic effects and side effects.Results The significant difference in symptoms between before and after treatment with ziprasidone was found(d=3.52,95%CI(2.86,4.18),χ2=108.78,P0.01).Comparison between ziprasidone and the other antipsychotics at 2nd weekend after treatment and at the end of trials showed that there was no significant difference with respect to the clinical efficacy.The occurent rate of nausea and vomit in ziprasidone group was significantly higher than that in the other antipsychotics group,but the rates of weight gain and EPS were lower in ziprasidone group.Conclusion Ziprasidone has a similar clinical efficacy comparing with controlled antipsychotics.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To study the efficacy and side effects of ziprasidone in treatment of patients with schizophrenia.Methods A total of 14 comparative studies of ziprasidone and the other antipsychotics in the treatment of patients with schizophrenia were analyzed by meta-analysis in therapeutic effects and side effects.Results The significant difference in symptoms between before and after treatment with ziprasidone was found(d=3.52,95%CI(2.86,4.18),χ2=108.78,P0.01).Comparison between ziprasidone and the other antipsychotics at 2nd weekend after treatment and at the end of trials showed that there was no significant difference with respect to the clinical efficacy.The occurent rate of nausea and vomit in ziprasidone group was significantly higher than that in the other antipsychotics group,but the rates of weight gain and EPS were lower in ziprasidone group.Conclusion Ziprasidone has a similar clinical efficacy comparing with controlled antipsychotics.
Key concepts: Ziprasidone, Schizophrenia (object-oriented programming), Significant difference, Nausea, Medicine, Clinical efficacy, Internal medicine, Psychiatry